Pharma Major Lupin announced that it has received final approval for its Clobetasol Propionate Lotion, 0.05% from the United States Food and Drug Administration (FDA) to market a generic version of Galderma Laboratories, L.P.'s Clobex Lotion, 0.05%.

Lupin’s Clobetasol Propionate Lotion, 0.05% is the AB rated generic equivalent of Galderma Laboratories, L.P.'s Clobex Lotion, 0.05%. It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, in patients 18 years of age or older.

Clobex Lotion, 0.05% had US sales of USD 14.3 million (IMS MAT June 2017).

Shares of the company declined Rs 35.45, or 3.43%, to trade at Rs 997.00. The total volume of shares traded was 61,436 at the BSE (2.43 p.m., Monday).